{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T17:10:06Z","timestamp":1736010606865,"version":"3.32.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00108-005-1501-y","type":"journal-article","created":{"date-parts":[[2005,9,29]],"date-time":"2005-09-29T07:30:24Z","timestamp":1127979024000},"page":"1399-1404","source":"Crossref","is-referenced-by-count":1,"title":["Moderne antirheumatische Pharmakotherapie","Up-to-date antirheumatic therapy: Methotrexate vs. biologicals"],"prefix":"10.1007","volume":"46","author":[{"given":"J.","family":"Sautner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. F.","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1501_CR1","first-page":"1072","volume":"43","author":"Braun","year":"2004","unstructured":"Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides \u2014 the current state. Drugs 43: 1072\u20131084","journal-title":"Drugs"},{"key":"1501_CR2","doi-asserted-by":"crossref","first-page":"OP0013","DOI":"10.1136\/ard.2003.017160","volume":"64","author":"Breedveld","year":"2005","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al. (2005) The efficacy and safety of Adalimumab (Humira\u00ae) plus MTX vs. Adalimumab alone or MTX alone in the early treatment of rheumatoid arthritis (RA): 1- and 2-year results of the PREMIER study. Ann Rheum Dis 64 (Suppl III): OP0013, 60","journal-title":"Ann Rheum Dis"},{"key":"1501_CR3","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"Bresnihan","year":"1998","unstructured":"Bresnihan B, Alvaro-Garcia JM, Cobby et al. (1998) Treatment of Rheumatoid Arthritis with recombinant human Interleukin-1 receptor-antagonist. Arthritis Rheum 41: 2196\u20132204","journal-title":"Arthritis Rheum"},{"key":"1501_CR4","first-page":"OP0105","volume":"2004","author":"Burmester","year":"2004","unstructured":"Burmester GR et al. (2004) Efficacy and safety of Adalimumab (Humira\u00ae) in European clinical practice: The REACT trial. EULAR 2004: OP0105","journal-title":"EULAR"},{"key":"1501_CR5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"Cohen","year":"1999","unstructured":"Cohen S, Hurd E, Cush J et al. (1999) Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients. Arthritis Rheum 42: 273","journal-title":"Arthritis Rheum"},{"key":"1501_CR6","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572\u20132581","journal-title":"N Engl J Med"},{"key":"1501_CR7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M et al. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105\u20131110","journal-title":"Lancet"},{"key":"1501_CR8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in RA. Ann Rev Immun 14: 397\u2013440","journal-title":"Ann Rev Immun"},{"key":"1501_CR9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al. (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727\u2013735","journal-title":"Arthritis Rheum"},{"key":"1501_CR10","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.61.suppl_2.ii2","volume":"61","author":"Furst","year":"2002","unstructured":"Furst DE, Breedveld FC, Kalden JR et al. (2002) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 61 (Suppl II): ii2\u2013ii7","journal-title":"Ann Rheum Dis"},{"key":"1501_CR11","unstructured":"Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Zeben D, Kerstens PJSM, Hazes JMW, Zwinderman AE, Breedveld FC (2005) Clinical and radiological efficacy of different treatment strategies. Two year follow-up of the BEST study. Ann Rheum Dis 64 (Suppl III) S58, OP 007"},{"key":"1501_CR12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64: 296\u2013298","journal-title":"Ann Rheum Dis"},{"key":"1501_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","volume":"50","author":"Keystone","year":"2004","unstructured":"Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, de Vries T, Burge DJ (2004) Once-weekly administration of 50\u00a0mg Etanercept in patients with active rheumatoid arthritis. Arthritis Rheum 50: 353\u2013363","journal-title":"Arthritis Rheum"},{"key":"1501_CR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP et al. (2004) TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes). Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675\u2013681","journal-title":"Lancet"},{"key":"1501_CR15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907\u20131915","journal-title":"N Engl J Med"},{"key":"1501_CR16","first-page":"114","volume":"23","author":"Leeb","year":"1996","unstructured":"Leeb BF, Smolen JS (1996) \u201eLow dose\u201c Methotrexate therapy in rheumatoid arthritis \u2014 an update. Acta Med Austr 23: 114\u2013119","journal-title":"Acta Med Austr"},{"key":"1501_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00115677-199804060-00002","volume":"4","author":"Leeb","year":"1998","unstructured":"Leeb BF, Weber K, Smolen JS (1998) Rheumatoid arthritis diagnosis and screening. Dis Manag Health Out 4: 315\u2013324","journal-title":"Dis Manag Health Out"},{"key":"1501_CR18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/rheumatology\/keh484","volume":"44","author":"Leeb","year":"2005","unstructured":"Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B (2005) The patient\u2019s perspective and disease activity indexes. Rheumatology 44: 360\u2013365","journal-title":"Rheumatology"},{"key":"1501_CR19","unstructured":"Leeb BF, Dunky A, Br\u00f6ll H et al. (2005) The economic burden of rheumatoid arthritis. Ann Rheum Dis (Suppl) EULAR 2005, Vienna."},{"key":"1501_CR20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342: 763\u2013769","journal-title":"N Engl J Med"},{"key":"1501_CR21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR et al. (1998) Therapeutic efficacy of multiple intravenous infusions of Anti-Tumor necrosis factor-\u03b1 monoclonal antibody combined with low-dose weekly MTX in rheumatoid arthritis. Arthritis Rheum 41: 1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"1501_CR22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932\u20131939","journal-title":"Lancet"},{"key":"1501_CR23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385\u2013390","journal-title":"Lancet"},{"key":"1501_CR24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761\u20131769","journal-title":"Arthritis Rheum"},{"key":"1501_CR25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","volume":"46","author":"O","year":"2002","unstructured":"O\u2019Dell JR, Leff R, Paulsen G et al. (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 1164\u20131170","journal-title":"Arthritis Rheum"},{"key":"1501_CR26","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593\u20131610","journal-title":"Gastroenterology"},{"key":"1501_CR27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1563-258X.2003.03036.x","volume":"153","author":"Sautner","year":"2003","unstructured":"Sautner J, Leeb BF (2003) Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies. Wien Med Wochenschr 153: 304\u2013308","journal-title":"Wien Med Wochenschr"},{"key":"1501_CR28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","volume":"353","author":"Smolen","year":"1999","unstructured":"Smolen JS, Kalden JR, Scott DL et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind randomized multicentre trial. Lancet 353: 259\u2013266","journal-title":"Lancet"},{"key":"1501_CR29","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"St","year":"2004","unstructured":"St.Clair EW, van der Heijde DM, Smolen JS et al. (2004) ASPIRE (Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group): Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432\u20133443","journal-title":"Arthritis Rheum"},{"key":"1501_CR30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"Weinblatt","year":"1985","unstructured":"Weinblatt ME, Coblyn JS, Fox DA (1985) Efficacy of low-dose oral pulse MTX in RA. N Engl J Med 312: 818\u2013822","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1501-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-005-1501-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1501-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T16:28:21Z","timestamp":1736008101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-005-1501-y"}},"subtitle":["Niedermolekulare Substanzen vs. Biologicals"],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s00108-005-1501-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}